An important prospect of future studies would be also to identify PSGR odorant antagonists (other than α-ionone which is irritant and harmful, side effects that would limit its use) as potential new anti-cancer agents probably possessing low side effects since the PSGR is not widely expressed in normal tissues. This evidence concerns the gene OR51E2 and cancer.